JAK2 and myelofibrosis: Both patients in our study with a JAK2 V617F mutation also responded, extending prior observations that reported 3/4 responses in patients with JAK2-positive myelofibrosis treated with panobinostat.16 The ability of panobinostat to target JAK2 mutant bone marrow disease provides some rationale for combining this drug with JAK2 inhibitors in future studies.